AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

NZ stocks end lower while Eroad tanks
Markets Market Close

NZ stocks end lower while Eroad tanks

The S&P/NZX 50 Index dropped 99.89 points or 0.75% to 13,289.21.

Jamie Gray 17 Oct 2025
Macpac NZ profits drop 71% as softer sales hit margins
Retail

Macpac NZ profits drop 71% as softer sales hit margins

The sales drop in New Zealand was larger than Kathmandu's.

Gregor Thompson 17 Oct 2025
Eroad shares slump 23% as it shifts focus from North America
Markets

Eroad shares slump 23% as it shifts focus from North America

Eroad cuts North America exposure, impairing $150m in assets.

Rebecca Howard 17 Oct 2025
$55m deal secures Santana mining land
Primary Sector

$55m deal secures Santana mining land

The gold miner now owns all the land where its best mining prospects lie.  

Pattrick Smellie 17 Oct 2025